A public–private partnership model for COVID-19 diagnostics

Krijger, Peter H.L.; Hoek, Tim A.; Boersma, Sanne; Donders, Lieke I P M; Broeders, Maaike; Pieterse, Mark; Toonen, Pim W.; Logister, Ive; Verhagen, Bram M.P.; Verstegen, Marjon J.A.M.; Ravesteyn, T.W. van; Roymans, Rene J T M; Mattiroli, Francesca; Vandesompele, Jo; Nijhuis, Monique; Meijer, S; Weert, Anton van; Dekker, Edwin; Dom, Fred J; Ruijtenbeek, Rob; Velden, Lieven B J van der; Bovenkamp, Jeroen H.B. Van de; Bosch, Martijn; Laat, Wouter de; Tanenbaum, Marvin E.

doi:10.1038/s41587-021-01080-6

Cited by 7 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, there has been recent progress on highly automated workflows for PCR diagnostics [61, 62, 63] that require fewer lab technicians. One example is endpoint PCR [64], which uses a waterbath instead of the more common piezoelectric system, for higher-throughput thermal cycling at lower cost.…”

Section: Implementation Feasibilitymentioning

confidence: 99%

“…Rapidly recruiting skilled technicians when a pandemic is detected is another option, but this would be difficult to do in 1-2 months and only about 1/1000 people are currently employed in the medical diagnostics industry in the US [60]. Alternatively, there has been recent progress on highly automated workflows for PCR diagnostics [61, 62, 63] that require fewer lab technicians. One example is endpoint PCR [64], which uses a waterbath instead of the more common piezoelectric system for higher throughput thermal cycling at lower cost.…”

Section: Appendicesmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced testing can substantially improve defence against several types of respiratory virus pandemic

Petrie,

Hay,

Srimokla

et al. 2024

Preprint

View full text Add to dashboard Cite

Mass testing to identify and isolate infected individuals is a promising approach for reducing harm from the next acute respiratory virus pandemic, potentially avoiding the need for indiscriminate social distancing measures whilst averting hospitalizations and deaths. To understand scenarios where mass testing might or might not be a viable intervention, here we modelled how effectiveness depends both on characteristics of the pathogen (R0, time to peak viral load) and on the testing strategy (limit of detection, testing frequency, test turnaround time, adherence). We base time-dependent test sensitivity and time-dependent infectiousness on an underlying viral load trajectory model. We show that given moderately high public adherence, achievable frequent testing can prevent as many transmissions as more costly interventions such as school or business closures. With very high adherence and fast, frequent, and more sensitive testing, we show that most respiratory virus pandemics could be controlled with mass testing alone.

show abstract

Section: Implementation Feasibilitymentioning

confidence: 99%

Section: Appendicesmentioning

confidence: 99%

Enhanced testing can substantially improve defence against several types of respiratory virus pandemic

Petrie,

Hay,

Srimokla

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…As a hypothetical scenario, assuming it requires a single aspiration-dispense cycle with a hypothetical 1 second for each step plus 1 second for pipette movement for the same number of samples, it will require approximately 4.5 hours to execute this single task if a single-channel pipetting instrument is used. Extrapolation of this simple example to systems, which are able to handle up to 14,000 samples per day, outlines a very clear overview of how critical such systems are as throughput increases[24].…”

Section: Research Applications Utilising Automated Liquid Handling De...mentioning

confidence: 99%

Automated liquid-handling operations for robust, resilient, and efficient bio-based laboratory practices

Torres‐Acosta

Lye

Dikicioglu

2022

Preprint

View full text Add to dashboard Cite

Increase in the adoption of liquid handling devices (LHD) can facilitate experimental activities. Initially adopted by businesses and industry-based laboratories, the practice has also moved to academic environments, where a wide range of non-standard/non-typical experiments can be performed. Current protocols or laboratory analyses require researchers to transfer liquids for the purpose of dilution, mixing, or inoculation, among other operations. LHD can render laboratories more efficient by performing more experiments per unit of time, by making operations robust and resilient against external factors and unforeseen events such as the COVID-19 pandemic, and by remote operation. The present work reviews literature that reported the adoption and utilisation of LHD available in the market and presents examples of their practical use. Applications demonstrate the critical role of automation in research development and its ability to reduce human intervention in the experimental workflow. Ultimately, this work will provide guidance to academic researchers to determine which LHD can fulfil their needs and how to exploit their use in both conventional and non-conventional applications. Furthermore, the breadth of applications and the scarcity of academic institutions involved in research and development that utilise these devices highlights an important area of opportunity for shift in technology to maximize research outcomes.

show abstract

“…Inactivating buffers have recently been developed for that purpose, allowing for safe NAAT, simultaneously inactivating and preserving clinical samples. An example of such a pathogen inactivating, RNA/DNA stabilizing transport medium for in vitro diagnostic testing using PCR methods is the InActiv Blue medium (InActiv Blue, Beernem, Belgium) [4][5][6][7][8][9] .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a novel respiratory virus inactivating buffer for parallel RT-qPCR and quick antigen testing

Deprez,

Steyaert,

Claeys

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Since the COVID-19 pandemic, many hospitals implemented a dual testing procedure for SARS-CoV-2 to assess the infection risk of an admitted patient. To allow for a short turn-around time, rapid antigen (Ag) testing via lateral flow tests (LFT) is combined with nucleic acid amplification testing (NAAT), requiring two nasopharyngeal swab collections. In this study, a novel, universal pathogen inactivation buffer (DNA/RNA Defend Pro (DRDP)) was evaluated for SARS-CoV-2 inactivation and simultaneous Ag and DNA/RNA stabilization. In an emergency department setting of a General Hospital in Ghent (Belgium), patients were tested for SARS-CoV-2, whereby a LFT for Ag detection (Abbott Panbio COVID-19 Ag Rapid Test) was performed in combination with sample collection for NAAT (Abbott Alinity m). Left-over buffers from LFT were diluted in DRDP to evaluate LFT and NAAT results after dilution. Thirty-six patients were included in the data analysis. Twenty-three diagnostic LFT results were available in the laboratory information system of which all corresponded with results after dilution with DRDP. When correlating NAAT results, seven out of eight positive test results were in agreement, compared to twenty-three out of twenty-five negative results. For thirty-four out of thirty-six samples, LFT and NAAT after dilution with DRDP yielded the same conclusion. Additionally, RNA stability in DRDP was demonstrated when stored for three days at room temperature. At the extreme, a sample stored in the DRDP buffer for 53 days at room temperature was still very positive (Cq 21.95). We demonstrated that, for the first time, a novel collection buffer could inactivate a pathogen (SARS-CoV-2) while also preserving antigen (for rapid antigen testing) and RNA (for molecular testing). This novel buffer holds promise for a single specimen to be used for both antigen and molecular testing in a safe working environment.

show abstract

A public–private partnership model for COVID-19 diagnostics

Cited by 7 publications

References 2 publications

Enhanced testing can substantially improve defence against several types of respiratory virus pandemic

Enhanced testing can substantially improve defence against several types of respiratory virus pandemic

Automated liquid-handling operations for robust, resilient, and efficient bio-based laboratory practices

Evaluation of a novel respiratory virus inactivating buffer for parallel RT-qPCR and quick antigen testing

Contact Info

Product

Resources

About